All In Biotech

Drug Trial Radar · NCT06790121

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of 3 Subcutaneous Dose Regimens of Lunsekimig (SAR443765) in Adult Participants With Moderate-to-severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

150

Actual

Start

Jan 30, 2025

Primary completion

Feb 12, 2026

Study completion Apr 9, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with moderate-to-severe atopic dermatitis (AD). This study explores the efficacy and safety of 3 subcutaneous (SC) dose regimens of lunsekimig in adult participants with moderate-to-severe AD who have a documented history, within 6 months prior to baseline, of an inadequate response to topical treatments or for whom topical therapies are not advised. The study consists of 6 arms: 3 parallel dosing regimens and matching placebo arms. Additionally, participants have the option of engaging in a dense pharmacokinetic/pharmodynamic (PK/PD) sampling subgroup. The study duration will be up to approximately 36 weeks, including up to 4 weeks of screening, 24 weeks of treatment period and an 8-week safety follow-up period.

Conditions

  • Dermatitis Atopic

Interventions

  • LunsekimigDrug

    Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

  • PlaceboDrug

    Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in Eczema Area and Severity Index (EASI) score from baseline to Week 24Time frame: From Baseline throughout the study, up to Week 24

Locations

52 sites in 4 countries. Site status is shown where the registry gives one.

  • T. Joseph Raoof MD Inc-Site Number: 8400004

    Encino, California

  • Integrative Skin Science and Research-Site Number: 8400002

    Sacramento, California

  • Clinical Trials Research Institute-Site Number: 8400003

    Thousand Oaks, California

  • Skin Care Research-Site Number: 8400013

    Boca Raton, Florida

  • Driven Research LLC-Site Number: 8400020

    Coral Gables, Florida

  • Revival Research Institute, LLC-Site Number: 8400021

    Evans, Georgia

  • Treasure Valley Medical Research-Site Number: 8400026

    Boise, Idaho

  • Southern Indiana Clinical Trials-Site Number: 8400024

    New Albany, Indiana

  • Indiana Clinical Trials Center, P.C.-Site Number: 8400018

    Plainfield, Indiana

  • Optima Research-Site Number: 8400019

    Plainfield, Indiana

  • Options Research Group-Site Number: 8400012

    West Lafayette, Indiana

  • DS Research - Kentucky-Site Number: 8400005

    Louisville, Kentucky

  • Clinical Trials Management LLC-Site Number: 8400010

    Covington, Louisiana

  • Beacon Clinical Research-Site Number: 8400006

    Quincy, Massachusetts

  • Somerset Skin Centre-Site Number: 8400009

    Troy, Michigan

  • Medisearch LLC-Site Number: 8400017

    Saint Joseph, Missouri

  • Skin Cancer and Dermatology Institute-Site Number: 8400011

    Reno, Nevada

  • Icahn School of Medicine at Mount Sinai-Site Number: 8400023

    New York, New York

  • Red River Research Partners-Site Number: 8400008

    Fargo, North Dakota

  • Health Concepts-Site Number: 8400025

    Rapid City, South Dakota

  • DermResearch-Site Number: 8400014

    Austin, Texas

  • Progressive Clinical Research-Site Number: 8400001

    San Antonio, Texas

  • Burien US-WA 98168 Dermatology of Seattle and Bellevue-Site Number: 8400015

    Burien, Washington

  • Investigational Site Number: 0203003

    Prague, Czechia

  • Investigational Site Number: 0203001

    Prague, Czechia

  • Investigational Site Number: 0203004

    Prague, Czechia

  • Investigational Site Number: 0203002

    Prague, Czechia

  • Investigational Site Number: 3920005

    Asahikawa-shi, Japan

  • Investigational Site Number: 3920003

    Fukuoka, Japan

  • Investigational Site Number: 3920004

    Kofu, Japan

  • Investigational Site Number: 3920002

    Mibu, Japan

  • Investigational Site Number: 3920006

    Nerima-ku, Japan

  • Investigational Site Number: 3920001

    Ōta-ku, Japan

  • Investigational Site Number: 3920008

    Tachikawa-shi, Japan

  • Investigational Site Number: 3920007

    Yokohama, Japan

  • Investigational Site Number: 6160014

    Bochnia, Poland

  • Investigational Site Number: 6160006

    Bydgoszcz, Poland

  • Investigational Site Number: 6160010

    Jelenia Góra, Poland

  • Investigational Site Number: 6160007

    Katowice, Poland

  • Investigational Site Number: 6160003

    Katowice, Poland

Showing 40 of 52 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.